TY - JOUR
T1 - Lymphovascular Invasion and pT Stage Are Prognostic Factors in Patients Treated with Radical Nephroureterectomy for Localized Upper Urinary Tract Transitional Cell Carcinoma
AU - Kim, Dong Suk
AU - Lee, Young Hoon
AU - Cho, Kang Su
AU - Cho, Nam Hoon
AU - Chung, Byung Ha
AU - Hong, Sung Joon
PY - 2010/2
Y1 - 2010/2
N2 - Objectives: To investigate the prognostic significance of lymphovascular invasion (LVI) in patients with localized upper urinary tract transitional cell carcinoma (UUT-TCC) after radical nephroureterectomy. Methods: The clinical records of 271 patients with UUT-TCC who underwent radical nephroureterectomy between 1986 and 2006 were reviewed. Patients with pT4 stage, lymph node involvement, or distant metastasis were excluded. A total of 238 patients with pTa-3N0M0 were eligible. The prognostic significance of various clinicopathologic factors was analyzed using univariate and multivariate analysis. The mean age was 64.1 years (range, 25-91 years) and the median follow-up duration was 53.4 months (range, 3-240 months). Results: LVI was present in 31 patients (13%). LVI was related to higher pT stage, high tumor grade, sessile architecture, and squamous differentiation. On univariate analysis, tumor architecture, squamous differentiation, LVI, tumor grade, and pT stage influenced disease-specific survival. On multivariate analysis, LVI (hazards ratio [HR], 2.33; P = .014) and pT stage (HR, 2.07; P = .021) showed significantly different rates of disease-specific survival. Patients were classified according to pT stage and LVI. The high-risk group (pT3 and LVI+) showed significantly worse disease-specific survival than the low- (pT ≤ 2 and LVI-) or intermediate-risk groups (pT3 and LVI-, pT ≤ 2 and LVI+) (P <.001 and P = .032, respectively). Conclusions: LVI and pT stage are significant prognostic factors for recurrence-free and cancer-specific survivals in patients with localized UUT-TCC. LVI and pT stage would be helpful for selecting patients who are appropriate for postoperative adjuvant chemotherapy.
AB - Objectives: To investigate the prognostic significance of lymphovascular invasion (LVI) in patients with localized upper urinary tract transitional cell carcinoma (UUT-TCC) after radical nephroureterectomy. Methods: The clinical records of 271 patients with UUT-TCC who underwent radical nephroureterectomy between 1986 and 2006 were reviewed. Patients with pT4 stage, lymph node involvement, or distant metastasis were excluded. A total of 238 patients with pTa-3N0M0 were eligible. The prognostic significance of various clinicopathologic factors was analyzed using univariate and multivariate analysis. The mean age was 64.1 years (range, 25-91 years) and the median follow-up duration was 53.4 months (range, 3-240 months). Results: LVI was present in 31 patients (13%). LVI was related to higher pT stage, high tumor grade, sessile architecture, and squamous differentiation. On univariate analysis, tumor architecture, squamous differentiation, LVI, tumor grade, and pT stage influenced disease-specific survival. On multivariate analysis, LVI (hazards ratio [HR], 2.33; P = .014) and pT stage (HR, 2.07; P = .021) showed significantly different rates of disease-specific survival. Patients were classified according to pT stage and LVI. The high-risk group (pT3 and LVI+) showed significantly worse disease-specific survival than the low- (pT ≤ 2 and LVI-) or intermediate-risk groups (pT3 and LVI-, pT ≤ 2 and LVI+) (P <.001 and P = .032, respectively). Conclusions: LVI and pT stage are significant prognostic factors for recurrence-free and cancer-specific survivals in patients with localized UUT-TCC. LVI and pT stage would be helpful for selecting patients who are appropriate for postoperative adjuvant chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=75349095748&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=75349095748&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2009.07.1350
DO - 10.1016/j.urology.2009.07.1350
M3 - Article
C2 - 20018349
AN - SCOPUS:75349095748
SN - 0090-4295
VL - 75
SP - 328
EP - 332
JO - Urology
JF - Urology
IS - 2
ER -